Merck reported second-quarter 2026 sales of $16.3 billion, up 5% year over year, while non-GAAP EPS came in at $2.13, as the company continued to advance a broad pipeline with multiple regulatory and clinical milestones. The quarter also included approval and label-expansion momentum across oncology, vaccines and cardiovascular medicine.
In oncology, Merck said the FDA approved KEYTRUDA and KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for certain adults with PD-L1-positive platinum-resistant ovarian cancer, based on Phase 3 KEYNOTE-B96 data. The company also said it secured additional regulatory progress for other KEYTRUDA-based regimens during the quarter.
Merck highlighted progress in vaccines as well, noting that ENFLONSIA was approved in Europe for the prevention of RSV lower respiratory tract disease in newborns and infants during their first RSV season, supported by Phase 2b/3 CLEVER and Phase 3 SMART trials. The company said this added to its broader efforts in infectious disease and prevention.
In cardiovascular disease, Merck pointed to positive topline results from its Phase 3 CORALreef trials evaluating enlicitide decanoate for adults with hyperlipidemia. It also said the FDA granted priority review to a supplemental Biologics License Application for WINREVAIR, seeking a label update supported by the Phase 3 ZENITH trial, and that WINREVAIR continued to show benefit in the Phase 3 HYPERION study.
Merck said the quarter’s operating results were affected by a large acquisition-related charge in the prior quarter, but the company continued to invest heavily in R&D and commercial capabilities. It added that the pipeline remains a central focus as it looks toward future growth and additional launches.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!